KZIAStockKAZIA THERAPEUTICS LTD
Verdicts genuinely change. Free email alert the moment KZIA's does — no target price to set, unlike a price alert.
Stable Ratio screen, 3 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
KAZIA THERAPEUTICS LTD (KZIA) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
435 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant · status tracked since Nov 17, 2026
No change to KZIA’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from the status this page publishes, last on Nov 20, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $42.2M as of 2026-11-19.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 30.00% | Pass(30.0pp buffer) |
| Interest-bearing investments | 109.93% | 30.00% | Fail(79.9pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Fail 3 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Interest-bearing investments | 97.68% | 33.00% | Fail(64.7pp over) |
| Non-liquid assets | 1.88% | at least 20.00% | Fail(18.1pp below the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
| Net liquid assets per share | $30.3M | under mkt cap $42.2M | Pass |
MSCI Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 97.68% | 33.33% | Fail(64.3pp over) |
| Accounts receivable | 98.12% | 33.33% | Fail(64.8pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 97.68% | 33.33% | Fail(64.3pp over) |
| Accounts receivable | 98.12% | 50.00% | Fail(48.1pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 187.89% | 33.00% | Fail(154.9pp over) |
| Accounts receivable | 0.85% | 33.00% | Pass(32.1pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 247.00% | 49.00% | Fail(198.0pp over) |
| Accounts receivable | 1.12% | 49.00% | Pass(47.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Fail 2 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 247.00% | 33.33% | Fail(213.7pp over) |
| Accounts receivable | 248.13% | 49.00% | Fail(199.1pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from KZIA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $27.2K | 2025-12-31 | Revenue |
| Interest-bearing debtShort and long-term borrowings | $0 | 2025-12-31 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $46.4M | 2025-12-31 | CashAndCashEquivalents |
| Total assetsBalance sheet total | $47.5M | 2025-12-31 | Assets |
| Market capDenominator for AAOIFI | $42.2M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $11.7B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $17.4B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2025-12-31 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Interim report (foreign issuer) (6-K) filed 2026-03-19, period ended 2025-12-31. Income statement: Annual report (foreign issuer) (20-F) filed 2025-11-07, period ended 2025-12-31. Screened 2026-11-19.
-
Total assets$47.5M
Assets· period ended 2025-12-31 · 6-K filed 2026-03-19 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2025-12-31 · no filing link for this figure -
Cash and interest-bearing securities$46.4M
CashAndCashEquivalents· period ended 2025-12-31 · 6-K filed 2026-03-19 -
Receivables$210.9K
TradeAndOtherCurrentReceivables· period ended 2025-12-31 · 6-K filed 2026-03-19 -
Revenue$27.2K
Revenue· period ended 2025-06-30 · 20-F filed 2025-11-07 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2025-12-31 · no filing link for this figure -
Market cap$42.2MMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link
4 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for KZIA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-19 Unverified → Pass filing re-screen
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 3 pass and 4 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-11-19.
No standard's deciding ratio sits within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio (0.0% against a 30% line) would only fail if the market cap fell by 100%, to $0.
AAOIFI's investments ratio is $46.4M cash and interest-bearing investments over a market cap of $42.2M (as of 2026-11-19), 109.9% against a 30% line.
It would pass if the market cap rose above $154.7M (+266%).
AAOIFI would then pass, and the majority verdict would move from Not compliant to Compliant (4 of 7 decided standards passing).
At the screen's market cap, it would take $33.8M less cash and interest-bearing investments to clear the line.
AAOIFI would then pass, and the majority verdict would move from Not compliant to Compliant (7 of 7 decided standards passing, counting every standard that divides the same figure).
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Steven Cohen | Point72 Asset Management | $2M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $2M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 23.40 | BUY |
| Stochastic %K (14) | 10.34 | BUY |
| CCI (20) | -159.60 | BUY |
| Williams %R (14) | -89.66 | BUY |
| MACD (12,26,9) | -0.18 | SELL |
| ROC (10) | -31.48 | SELL |
| Momentum (10) | -2.26 | SELL |
| EMA (10) | 6.04 | SELL |
| SMA (10) | 6.25 | SELL |
| EMA (20) | 6.79 | SELL |
| SMA (20) | 7.12 | SELL |
| EMA (30) | 7.36 | SELL |
| SMA (30) | 7.35 | SELL |
| EMA (50) | 8.31 | SELL |
| SMA (50) | 8.35 | SELL |
| EMA (100) | 9.60 | SELL |
| SMA (100) | 10.74 | SELL |
| EMA (200) | 9.64 | SELL |
| SMA (200) | 10.55 | SELL |
About KAZIA THERAPEUTICS LTD
Healthcare · Biotechnology
Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group; as well as licence agreement with Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | BEARISH | 28 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.